Inhibitex

Biopharmaceutical company focused on novel antibody-based products for serious hospital-associated bacterial and fungal infections

Sectors
Healthcare
Life Sciences
First Invested
2002
Public/PIPES
Company Status
IPO/Acquired
Acquired by Bristol Myers Squibb